CoChat
Sign Up
Cited by 83

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

CCL‐11 or Eotaxin‐1: an immune marker for ageing and accelerated ageing in neuro‐psychiatric disorders

Ivanovska, Mariya, Abdi, Zakee, Murdjeva, Marianna, Macedo, Danielle, Maes, Annabel, Maes, Michael·2020·Pharmaceuticals
DOI 10.3390/ph13090230PMC PMC7558796
Open this paper in CoChat — free account

Abstract

Background: CCL-11 (eotaxin) is a chemokine with an important role in allergic conditions. Recent evidence indicates that CCL-11 plays a role in brain disorders as well. This paper reviews the associations between CCL-11 and aging, neurodegenerative, neuroinflammatory and neuropsychiatric disorders. Methods: Electronic databases were searched for original articles examining CCL-11 in neuropsychiatric disorders. Results: CCL-11 is rapidly transported from the blood to the brain through the blood-brain barrier. Age-related increases in CCL-11 are associated with cognitive impairments in executive functions and episodic and semantic memory, and therefore, this chemokine has been described as an “Endogenous Cognition Deteriorating Chemokine” (ECDC) or “Accelerated Brain-Aging Chemokine” (ABAC). In schizophrenia, increased CCL-11 is not only associated with impairments in cognitive functions, but also with key symptoms including formal thought disorders. Some patients with mood disorders and premenstrual syndrome show increased plasma CCL-11 levels. In diseases of old age, CCL-11 is associated with lowered neurogenesis and neurodegenerative processes, and as a consequence, increased CCL-11 increases risk towards Alzheimer’s disease. Polymorphisms in the CCL-11 gene are associated with stroke. Increased CCL-11 also plays a role in neuroinflammatory disease including multiple sclerosis. In animal models, neutralization of CCL-11 may protect against nigrostriatal neurodegeneration. Increased production of CCL-11 may be attenuated by glucocorticoids, minocycline, resveratrol and anti-CCL11 antibodies. Conclusions: Increased CCL-11 production during inflammatory conditions may play a role in human disease including age-related cognitive decline, schizophrenia, mood disorders and neurodegenerative disorders. Increased CCL-11 production is a new drug target in the treatment and prevention of those disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ph13090230

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Eotaxin is correlated with many neurological conditions (neurodegenerative, neuroinflammatory, and neuropsychiatric disorders), earning names ECDC or ABAC.

    “Because eotaxin is correlated with so many neurological conditions (neurodegenerative, neuroinflammatory, and neuropsychiatric disorders), it has earned the name “Endogenous Cognition Deteriorating Chemokine” (ECDC) or “Accelerated Brain‐Aging Chemokine” (ABAC). 67”

    From Three Tiers to biological escape velocity: The quest to outwit aging (2022) · cites this paper as [67]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 83

  1. Foxman, 1997, Multistep navigation and the combinatorial control of leukocyte chemotaxis, J. Cell Biol., 139, 1349, 10.1083/jcb.139.5.1349 · DOI
  2. Murphy, 2000, International union of pharmacology. XXII. Nomenclature for chemokine receptors, Pharmacol. Rev., 52, 145
  3. Springer, 1994, Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm, Cell, 76, 301, 10.1016/0092-8674(94)90337-9 · DOI
  4. Wu, 1977, Purification and characterization of human and bovine platelet factor 4, Prep. Biochem., 7, 479
  5. Callewaere, 2007, Chemokines and chemokine receptors in the brain: Implication in neuroendocrine regulation, J. Mol. Endocrinol., 38, 355, 10.1677/JME-06-0035 · DOI
  6. Tani, 1994, Do chemokines mediate inflammatory cell invasion of the central nervous system parenchyma?, Brain Pathol., 4, 135, 10.1111/j.1750-3639.1994.tb00824.x · DOI
  7. Rostene, 2013, Current status of chemokines in the adult CNS, Prog. Neurobiol., 104, 67, 10.1016/j.pneurobio.2013.02.001 · DOI
  8. Teixeira, 2018, Revisiting the Role of Eotaxin-1/CCL11 in Psychiatric Disorders, Front. Psychiatr., 9, 241, 10.3389/fpsyt.2018.00241 · DOI
  9. Sirivichayakul, 2019, A new schizophrenia model: Immune activation is associated with induction of different neurotoxic products which together determine memory impairments and schizophrenia symptom dimensions, CNS Neurol. Disord. Drug Targets, 18, 124, 10.2174/1871527317666181119115532 · DOI
  10. Kindstedt, 2017, CCL11, a novel mediator of inflammatory bone resorption, Sci. Rep., 7, 5334, 10.1038/s41598-017-05654-w · DOI
  11. Sirivichayakul, 2019, Eotaxin, an Endogenous Cognitive Deteriorating Chemokine (ECDC), Is a Major Contributor to Cognitive Decline in Normal People and to Executive, Memory, and Sustained Attention Deficits, Formal Thought Disorders, and Psychopathology in Schizophrenia Patients, Neurotox. Res., 35, 122, 10.1007/s12640-018-9937-8 · DOI
  12. Tani, 1999, Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients, J. Clin. Investig., 103, 807, 10.1172/JCI5150 · DOI
  13. Eyre, 2012, Neuroplastic changes in depression: A role for the immune system, Psychoneuroendocrinology, 37, 1397, 10.1016/j.psyneuen.2012.03.019 · DOI · Paper page
  14. Stuart, 2014, Knockout of CXCR5 increases the population of immature neural cells and decreases proliferation in the hippocampal dentate gyrus, J. Neuroinflamm., 11, 31, 10.1186/1742-2094-11-31 · DOI
  15. Baruch, 2013, CNS-specific immunity at the choroid plexus shifts toward destructive Th2 inflammation in brain aging, Proc. Natl. Acad. Sci. USA, 110, 2264, 10.1073/pnas.1211270110 · DOI
  16. Yamagami, 1997, Monocyte chemoattractant protein-2 can exert its effects through the MCP-1 receptor (CC CKR2B), FEBS Lett., 400, 329, 10.1016/S0014-5793(96)01411-1 · DOI
  17. Jose, 1994, Eotaxin: A potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation, J. Exp. Med., 179, 881, 10.1084/jem.179.3.881 · DOI
  18. Ponath, 1996, Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils, J. Exp. Med., 183, 2437, 10.1084/jem.183.6.2437 · DOI
  19. Sallusto, 1997, Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells, Science, 277, 2005, 10.1126/science.277.5334.2005 · DOI · Paper page
  20. Pease, 2006, Asthma, allergy and chemokines, Curr. Drug Targets, 7, 3, 10.2174/138945006775270204 · DOI
  21. Martinelli, 2001, The CC chemokine eotaxin (CCL11) is a partial agonist of CC chemokine receptor 2b, J. Biol. Chem., 276, 42957, 10.1074/jbc.M103933200 · DOI
  22. Ogilvie, 2001, Eotaxin is a natural antagonist for CCR2 and an agonist for CCR5, Blood, 97, 1920, 10.1182/blood.V97.7.1920 · DOI
  23. Weng, 1998, Binding and functional properties of recombinant and endogenous CXCR3 chemokine receptors, J. Biol. Chem., 273, 18288, 10.1074/jbc.273.29.18288 · DOI
  24. Chazan, 2007, Role of eotaxin in the pathophysiology of asthma, Pneumonol. Alergol. Pol., 75, 180
  25. Lv, 2018, IL-37 inhibitsIL-4/IL-13-induced CCL11 production and lung eosinophilia in murine allergic asthma, Allergy, 73, 1642, 10.1111/all.13395 · DOI
  26. Amerio, 2003, Eotaxins and CCR3 receptor in inflammatory and allergic skin diseases: Therapeutical implications, Curr. Drug Targets Inflamm. Allergy, 2, 81, 10.2174/1568010033344480 · DOI
  27. Erin, 2002, Eotaxin receptor (CCR3) antagonism in asthma and allergic disease, Curr. Drug Targets Inflamm. Allergy, 1, 201, 10.2174/1568010023344715 · DOI
  28. Lacy, P. (2017). Chapter-2 Eosinophil Cytokines in Allergy. Cytokine Eff. Funct. Tissues, 173–218. · DOI
  29. Romagnani, 2002, Cytokines and chemoattractants in allergic inflammation, Mol. Immunol., 38, 881, 10.1016/S0161-5890(02)00013-5 · DOI
  30. Garcia, 2005, New chemokine targets for asthma therapy, Curr. Allergy Asthma Rep., 5, 155, 10.1007/s11882-005-0090-0 · DOI
  31. Elsner, 2004, Chemokine receptor antagonists: A novel therapeutic approach in allergic diseases, Allergy, 59, 1243, 10.1111/j.1398-9995.2004.00710.x · DOI
  32. Erickson, 2014, Rapid transport of CCL11 across the blood-brain barrier: Regional variation and importance of blood cells, J. Pharmacol. Exp., 349, 497, 10.1124/jpet.114.213074 · DOI · Paper page
  33. Jamaluddin, 2009, Eotaxin increases monolayer permeability of human coronary artery endothelial cells, Arter. Thromb. Vasc. Biol., 29, 2146, 10.1161/ATVBAHA.109.194134 · DOI
  34. Maes, 2019, Breakdown of the paracellular tight and adherens junctions in the gut and blood brain barrier and damage to the vascular barrier in patients with deficit schizophrenia, Neurotox. Res., 36, 306, 10.1007/s12640-019-00054-6 · DOI
  35. Parajuli, 2015, CCL11 enhances excitotoxic neuronal death by producing reactive oxygen species in microglia, Glia, 63, 2274, 10.1002/glia.22892 · DOI
  36. Zhu, 2017, Targeting CCR3 to Reduce Amyloid-β Production, Tau Hyperphosphorylation, and Synaptic Loss in a Mouse Model of Alzheimer’s Disease, Mol. Neurobiol., 54, 7964, 10.1007/s12035-016-0269-5 · DOI
  37. Xia, 1998, Immunohistochemical study of the beta-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer’s disease brains, Am. J. Pathol., 153, 31, 10.1016/S0002-9440(10)65542-3 · DOI
  38. Hoefer, 2017, The "aging factor" eotaxin-1 (ccl11) is detectable in transfusion blood products and increases with the donor’s age, Front. Aging Neurosci., 9, 402, 10.3389/fnagi.2017.00402 · DOI · Paper page
  39. Huber, 2018, An emerging role for eotaxins in neurodegenerative disease, Clin. Immunol., 189, 29, 10.1016/j.clim.2016.09.010 · DOI · Paper page
  40. Butcher, 2018, Association between plasma CCL11 (eotaxin-1) and cognitive status in older adults: Differences between rural and urban dwellers, Exp. Gerontol., 113, 173, 10.1016/j.exger.2018.10.004 · DOI
  41. Maes, 1995, Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression, Eur. Arch. Psychiatry Clin. Neurosci., 244, 325, 10.1007/BF02190412 · DOI
  42. Noto, 2014, Effects of risperidone on cytokine profile in drug-naïve first-episode psychosis, Int. J. Neuropsychopharmacol., 18, 4
  43. Noto, 2016, Depression, cytokine, and cytokine by treatment interactions modulate gene expression in antipsychotic naïve first episode psychosis, Mol. Neurobiol., 53, 5701, 10.1007/s12035-015-9489-3 · DOI
  44. Roomruangwong, C., Sirivichayakul, S., Carvalho, A.F., and Maes, M. (2019). The uterine-chemokine-brain axis: Menstrual cycle-associated symptoms (mcas) are in part mediated by CCL2, CCL5, CCL11, CXCL8 and CXCL10. Preprints, 2019090329. · DOI
  45. Hong, 2017, Abnormalities in chemokine levels in schizophrenia and their clinical correlates hhs public access, Schizophr. Res., 181, 63, 10.1016/j.schres.2016.09.019 · DOI
  46. Czepielewski, 2018, Telomere length and CCL11 levels are associated with gray matter volume and episodic memory performance in schizophrenia: Evidence of pathological accelerated aging, Schizophr. Bull., 44, 158, 10.1093/schbul/sbx015 · DOI
  47. Noto, 2015, High predictive value of immune-inflammatory biomarkers for schizophrenia diagnosis and association with treatment resistance, World J. Biol. Psychiatry, 27, 422, 10.3109/15622975.2015.1062552 · DOI
  48. Frydecka, 2018, Profiling inflammatory signatures of schizophrenia: A cross-sectional and meta-analysis study, Brain Behav. Immun., 71, 28, 10.1016/j.bbi.2018.05.002 · DOI
  49. Almulla, 2020, The neuroimmune and neurotoxic fingerprint of major neurocognitive psychosis or deficit schizophrenia: A supervised machine learning study, Neurotox. Res., 37, 753, 10.1007/s12640-019-00112-z · DOI
  50. Al-Dujaili, A.H., Mousa, R.F., Al-hakeim, H.K., and Maes, M. (2019). High mobility group protein 1 and dickkopf-related protein 1 in schizophrenia and treatment-resistant schizophrenia: Associations with interleukin-6, symptom domains, and neurocognitive impairments. Preprints, 2019120100. · DOI
  51. Teixeira, 2008, Increased serum levels of CCL11/eotaxin in schizophrenia, Prog. Neuropsychopharmacol. Biol. Psychiatry, 32, 710, 10.1016/j.pnpbp.2007.11.019 · DOI
  52. Magalhaes, 2014, Peripheral eotaxin-1 (CCL11) levels and mood disorder diagnosis in a population-based sample of young adults, J Psychiatr. Res., 48, 13, 10.1016/j.jpsychires.2013.10.007 · DOI · Paper page
  53. Barbosa, 2013, Chemokines in bipolar disorder: Trait or state?, Eur. Arch. Psychiatry Clin. Neurosci., 263, 159, 10.1007/s00406-012-0327-6 · DOI
  54. Simon, 2008, A detailed examination of cytokine abnormalities in Major Depressive Disorder, Eur. Neuropsychopharmacol., 18, 230, 10.1016/j.euroneuro.2007.06.004 · DOI · Paper page
  55. Garcıa-Marchena, N., Barrera, M., MestrePinto´, J.I., Araos, P., Serrano, A., Pe´rez-Maña´, C., Papaseit, E., Alías-Ferri, M., Ruiz, J.J., and De Fonseca, F.R. (2019). Inflammatory mediators and dual depression: Potential biomarkers in plasma of primary and substance-induced major depression in cocaine and alcohol use disorders. PLoS ONE, 14. · DOI
  56. Fontenelle, 2012, A cytokine study of adult patients with obsessive-compulsive disorder, Compr. Psychiatry, 53, 797, 10.1016/j.comppsych.2011.12.007 · DOI
  57. Cunha, 2015, Inflammation, neurotrophism and oxidative stress and childhood psychopathology in a large community sample, Acta Psychiatr. Scand., 134, 569
  58. Masi, 2015, Cytokine aberrations in autism spectrum disorder: A systematic review and meta-analysis, Mol. Psychiatry, 20, 440, 10.1038/mp.2014.59 · DOI
  59. Kuo, 2018, Inflammatory chemokine eotaxin-1 is correlated with age in heroin dependent patients under methadone maintenance therapy, Drug Alcohol Depend., 183, 19, 10.1016/j.drugalcdep.2017.10.014 · DOI
  60. Araos, 2016, Plasma Chemokines in patients with alcohol use disorders: Association of CCL11 (Eotaxin-1) with psychiatric comorbidity, Front. Psychiatry, 7, 214
  61. Scalzo, 2011, Serum levels of chemokines in Parkinson’s disease, NeuroImmunoModulation, 18, 240, 10.1159/000323779 · DOI
  62. Lindqvist, 2013, Cerebrospinal fluid inflammatory markers in Parkinson’s disease—Associations with depression, fatigue, and cognitive impairment, Brain Behav. Immun., 33, 183, 10.1016/j.bbi.2013.07.007 · DOI
  63. Khorramdelazad, 2020, Eotaxins and C-C chemokine receptor type 3 in Parkinson’s disease, Acta Neurol. Belg., 120, 589, 10.1007/s13760-018-01061-8 · DOI
  64. Chandra, 2017, Induction of adaptive immunity leads to nigrostriatal disease progression in mptp mouse model of parkinson’s disease, J. Immunol., 198, 4312, 10.4049/jimmunol.1700149 · DOI
  65. Weinshenker, 1996, Epidemiology of multiple sclerosis, Neurol. Clin., 14, 291, 10.1016/S0733-8619(05)70257-7 · DOI
  66. Bai, 2019, Cerebrospinal fluid and blood cytokines as biomarkers for multiple sclerosis: A systematic review and meta-analysis of 226 studies with 13,526 multiple sclerosis patients, Front. Neurosci., 13, 1026, 10.3389/fnins.2019.01026 · DOI
  67. Michael, 2013, Post-acute serum eosinophil and neutrophil-associated cytokine/chemokine profile can distinguish between patients with neuromyelitis optica and multiple sclerosis; and identifies potential pathophysiological mechanisms—A pilot study, Cytokine, 64, 90, 10.1016/j.cyto.2013.07.019 · DOI
  68. Tong, 2018, Elevated plasma chemokines for eosinophils in neuromyelitis optica spectrum disorders during remission, Front. Neurol., 9, 44, 10.3389/fneur.2018.00044 · DOI
  69. Casrouge, 2017, Multimarker risk stratification approach at multiple sclerosis onset, Clin. Immunol., 181, 43, 10.1016/j.clim.2017.05.019 · DOI
  70. Adzemovic, M.Z., Öckinger, J., Zeitelhofer, M., Hochmeister, S., Beyeen, A.D., Paulson, A., Gillett, A., Thessen Hedreul, M., Covacu, R., and Lassmann, H. (2012). Expression of Ccl11 associates with immune response modulation and protection against neuroinflammation in rats. PLoS ONE, 7. · DOI
  71. Khavinson, 2016, Protein of senility CCL11, “protein of juvenility” GDF11 and their role in age-related pathology, Adv. Gerontol., 29, 722
  72. Sharma, 2014, A blood-based biomarker panel to detect acute stroke, J. Stroke Cereb. Dis., 23, 910, 10.1016/j.jstrokecerebrovasdis.2013.07.034 · DOI
  73. Ritzel, 2017, CCL11 (Eotaxin-1) levels predict long-term functional outcomes in patients following ischemic stroke, Transl. Stroke Res., 8, 578, 10.1007/s12975-017-0545-3 · DOI
  74. Liang, 2017, Impact of tag single nucleotide polymorphisms (snps) in ccl11 gene on risk of subtypes of ischemic stroke in xinjiang han populations, Med. Sci. Monit., 23, 4291, 10.12659/MSM.905942 · DOI
  75. Zhao, 2012, Association of inflammatory gene polymorphisms with ischemic stroke in a Chinese Han population, J. Neuroinflammation, 9, 162, 10.1186/1742-2094-9-162 · DOI
  76. Munshi, 2015, Genetic determinants in ischaemic stroke subtypes: Seven-year findings and a review, Gene, 555, 250, 10.1016/j.gene.2014.11.015 · DOI
  77. Yang, 2011, Control of eotaxin-1 expression and release by resveratrol and its metabolites in culture human pulmonary artery endothelial cells, Am. J. Cardiovasc. Dis., 1, 16
  78. Main, 2006, A potent human anti-eotaxin1 antibody, CAT-213: Isolation by phage display and in vitro and in vivo efficacy, J. Pharmacol. Exp. Ther., 319, 1395, 10.1124/jpet.106.110734 · DOI
  79. Garwood, 2010, Anti-inflammatory impact of minocycline in a mouse model of tauopathy, Front. Psychiatry, 1, 136, 10.3389/fpsyt.2010.00136 · DOI · Paper page
  80. Kanabar, 2008, Heparin and structurally related polymers attenuate eotaxin-1 (CCL11) release from human airway smooth muscle, Br. J. Pharm., 154, 833, 10.1038/bjp.2008.109 · DOI
  81. Jahnsen, 1999, Glucocorticosteroids inhibit mRNA expression for eotaxin, eotaxin-2, and monocyte-chemotactic protein-4 in human airway inflammation with eosinophilia, J. Immunol., 163, 1545, 10.4049/jimmunol.163.3.1545 · DOI
  82. Stellato, 1997, Production of the novel C-C chemokine MCP-4 by airway cells and comparison of its biological activity to other C-C chemokines, J. Clin. Investig., 99, 926, 10.1172/JCI119257 · DOI
  83. Lilly, 1997, Expression of eotaxin by human lung epithelial cells: Induction by cytokines and inhibition by glucocorticoids, J. Clin. Investig., 99, 1767, 10.1172/JCI119341 · DOI

Cited by

Sorted by citations

Metadata

Authors
Ivanovska, M., Abdi, Z., Murdjeva, M., Macedo, D., Maes, A., & Maes, M.
Affiliations
  • Department of Microbiology and Immunology, Faculty of Pharmacy, Research Institute, Medical University-Plovdiv, 4002 Plovdiv, Bulgaria
  • Medical Faculty, Medical University-Plovdiv, 4002 Plovdiv, sBulgaria
  • Neuropsychopharmacology Laboratory, Drug Research, and Development Center, Faculty of Medicine, Universidade Federal do Ceará, Fortaleza 60455-760, Brazil
  • Kiezelweg 108, 3620 Lanaken, Belgium
  • Department of Psychiatry, Chulalongkorn University, Bangkok 10140, Thailand
ORCID
Venue
Pharmaceuticals
Publisher
MDPI AG
Published
2020-09-02
Volume
13
Issue
9
Pages
230
ISSN
1424-8247
DOI
10.3390/ph13090230
PMC
PMC7558796
Cited by
83
References
9
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review